Results 11 to 20 of about 14,877 (300)

Abciximab-Associated Pseudothrombocytopenia [PDF]

Circulation, 2000
A60-year-old woman was transferred for coronary angiography after a non–Q-wave myocardial infarction. She was treated with aspirin, metoprolol, unfractionated heparin, and abciximab administered as a weight-based bolus followed by infusion. A complete blood count in blood anticoagulated with EDTA (purple-top Vacutainer) was obtained shortly after her ...
Robert W. Battle, David J. Schneider, Matthew W. Watkins, Michael B. Holmes, Samer S. Kabbani   +4 more
openaire   +4 more sources

Abciximab-induced delayed profound thrombocytopaenia [PDF]

BMJ Case Reports, 2017
Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was ...
Jbara, Manar, Bhogal, Sukhdeep, Bajaj, Kailash, Chhabra, Lovely   +3 more
openaire   +5 more sources

Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion [PDF]

, 2002
BACKGROUND: GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Bertuglia, Silva, Giusti, Andrea
core   +4 more sources

Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives

Therapeutics and Clinical Risk Management, 2014
Artur Dziewierz,1 Tomasz Rakowski,1 Dariusz Dudek2 12nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland; 2Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland Abstract ...
Dziewierz A, Rakowski T, Dudek D
doaj   +2 more sources

The use of abciximab associated with primary angioplasty for treating acute myocardial infarction [PDF]

Arquivos Brasileiros de Cardiologia, 2002
OBJECTIVE: To assess the benefit resulting from the use of abciximab associated with primary angioplasty. The following parameters were analyzed in-hospital, at 30 days, and 6 months: (a) flow in the culprit artery; (b) ventricular function; (c) combined
Manuel Lisandro Hernández Brito, Newton F. Stadler de Souza Filho, Álvaro Vieira Moura, Luiz Augusto Lavalle, Rubens Zenobio Darwich, Marisa Leal, Eva Cantalejo Munhoz   +6 more
doaj   +2 more sources

Breaking the Barrier: Unraveling the No-Reflow Phenomenon in Cardiovascular Medicine. [PDF]

Catheter Cardiovasc Interv
ABSTRACT The no‐reflow phenomenon is a stubborn and often devastating complication in cardiovascular medicine, where blood flow is restored to an artery, yet the microvasculature remains unresponsive. First identified in 1967, this phenomenon has haunted clinicians and researchers alike, particularly in the context of acute myocardial infarction (AMI).
Howes S, Altaee O, Ramirez A, Calaquian L, Asif A, Stone C, Hammadah M, Roy D, Ramsey B, Chilton R.   +9 more
europepmc   +2 more sources

Modeling Versus Balancing Approaches to Addressing Instrumental Variables in Weighting: A Comparison of the Outcome-Adaptive Lasso, Stable Balancing Weighting, and Stable Confounder Selection. [PDF]

Pharmacoepidemiol Drug Saf
ABSTRACT Background Variable selection is essential for propensity score (PS)‐weighted estimators. Recent work shows that including instrumental variables (IVs), associated with only treatment but not with the outcome, can impact both the bias and precision of the PS‐weighted estimators.
Choi BY, Brookhart MA.
europepmc   +2 more sources

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. [PDF]

New England Journal of Medicine, 1999
BACKGROUND: In patients with refractory unstable angina, the platelet glycoprotein IIb/IIIa-receptor antibody abciximab reduces the incidence of cardiac events before and during coronary angioplasty.
Adgey, J. (Jennifer), Berger, J. (Jürgen), Goldmann, B. (Britta), Hamm, C.W. (Christian), Heeschen, C. (Christopher), Kootstra, J.G. (Jille), Miguel, C.M. (Carlos), Rutsch, W.R. (Wolfgang), Simoons, M.L. (Maarten), Vahanian, A.S. (Alec)   +9 more
core   +3 more sources

Sustainable Practices in Anti-VEGF Therapy: A 15-Year Bibliometric Analysis of Ranibizumab for Age-Related Macular Degeneration. [PDF]

J Ophthalmol
Objective: A bibliometric analysis was performed in the domain of ranibizumab and age‐related macular degeneration (AMD) to delineate current trends in international research dynamics and to provide a visual representation of research hotspots and challenges associated with ophthalmic drugs over the past 15 years.
Xiaodong L, Xia C, Xuewei Q, Dandan W, Yi Y, Zhilin L.   +5 more
europepmc   +2 more sources

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y₁₂ Inhibitor Prescribing. [PDF]

Clin Pharmacol Ther
P2Y12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend ...
Springer AN, Alicea LA, Gafari Y, Smith TB, Lynch S, Breman AM, Hodge JC, Pratt VM, Powell NR, Kreutz RP, Kobold DP, Eadon MT, Tillman EM, Shugg T, Skaar TC.   +14 more
europepmc   +2 more sources